Laurus Labs’ COVID Drug receives License
On Friday, pharmaceutical company Laurus Labs said that it had obtained a license from the Defense Research and Development Organization to produce and sell the COVID19 treatment drug 2-Deoxy-D-Glucose (2DG).
In addition, Laurus Labs said in a regulatory document that 2DG has received emergency approval from the Drugs Comptroller General of India (DCGI) and can be used for COVID19 patients in the country.
“It has applied for an emergency use authorization for 2DG from the Central Drug Standard Control Organization (CDSCO),” it added.
On June 28, pharmaceutical giant Dr Reddy announced the commercial launch of 2DG at the highest retail price of Rs 990 per bag. As a result, the trading price of 4,444 their shares on the BSE is Rs 674.20 per share, 1.08% higher than the closing price on the previous trading day.
